Majescor Resources Acquires Mining Division of Diagnos
Majescor Resources Acquires Mining Division of Diagnos
– Momentum Public Relations –
Press Release: March 15, 2017
OTTAWA, ONTARIO–(Marketwired – March 15, 2017) – Majescor Resources Inc. (“Majescor” or the “Company”) (TSX VENTURE:MJX) is pleased to announce the signing of an agreement with Diagnos Inc. (“DIAGNOS”) for the purchase of its assets from the mining division, including the Computer Aided Resources Detection System (“CARDS”), for total value of $800,000.
Under the terms of the agreement, on or before March 31, 2017, Majescor will issue 8,000,000 common shares of its share capital to DIAGNOS, at a deemed price of $0.10 per share, in payment for the acquisition of the assets, consisting of DIAGNOS’ mining claims, royalty agreements, and the CARDS system. Additionally, Majescor will remit to DIAGNOS (i) 50{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of any payment that Majescor receives from the royalty agreements forming part of the acquired assets, and (ii) 5{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of revenues generated by the commercialization of the CARDS system.
“This is a game changer for Majescor. It puts us in the forefront in becoming the leader in using artificial intelligence and machine learning for mineral exploration. DIAGNOS has over a 10-year track record of using and perfecting its CARDS system and we are excited about the added value that Majescor will now be able to provide to our own mineral projects as well as the potential for revenue-generating third party applications”, stated André Audet, President and CEO of Majescor.
The transaction is subject to terms and conditions such as receipt of all required regulatory approvals, including the approval of the TSX Venture Exchange. All monies quoted in this news release shall be stated and paid in lawful money of Canada.
About Majescor Resources Inc.
Majescor is a junior mining exploration company with an extensive portfolio of gold and diamond properties in Quebec.
Additional information about the Corporation is available under Majescor’s profile on SEDAR at www.sedar.com.
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively referred to herein as “forward-looking statements”) within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or are events or conditions that “will”, “would”, “may”, “could” or “should” occur or be achieved. This news release contains forward-looking statements, pertaining to, among other things, the following: the resumption of the trading of Majescor shares on the TSX Venture Exchange. Statements regarding future production, capital expenditures and development plans are subject to all of the risks and uncertainties normally incident to the exploration for and development and production of oil and gas that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. These risks include, but are not limited to, inflation or lack of availability of goods and services, environmental risks, drilling risks, regulatory changes and certain other known and unknown risks detailed from time to time in Majescor’s public disclosure documents, copies of which are available on Majescor’s SEDAR profile at www.sedar.com.
Although Majescor believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. Majescor’s actual results may differ materially from those expressed or implied in forward-looking statements and readers should not place undue importance or reliance on the forward-looking statements. Statements including forward-looking statements are made as of the date they are given and except as required by applicable securities laws, Majescor disclaims any intention or obligation to publically update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
CONTACT INFORMATION
-
Andre Audet
President & CEO
Majescor Resources Inc.
613-241-5333
613-422-0773 (FAX)
andre@evertonresources.com
www.majescor.com
- Published in Albert Mining, Mining, News Home
Canamex Resources shareholders re-elect six directors
Canamex Resources shareholders re-elect six directors
– Momentum Public Relations –
Press Release: March 14, 2017
Mr. Mark Billings reports
CANAMEX ANNOUNCES ALL MATTERS APPROVED AT AGM HELD ON MARCH 6, 2017
All matters were approved by shareholders at Canamex Resources Corp.’s annual general meeting held on March 6, 2017. Accordingly, the directors and officers of the company remain as follows:
- Mark Billings as chief executive officer, chairman and director;
- Gregory Hahn as presdient, chief operating officer and director;
- Jeb Handwerger as director;
- Frank Hogel as director;
- Dean McDonald as director;
- Mike Stark as director;
- Richard Barnett as secretary and chief financial officer.
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Canamex Resources Corp., Mining, News Home
Tetra Bio-Pharma (TBP:CSE) Enters into Binding Term Sheet for Two Products with Panag Pharma
Tetra Bio-Pharma Enters into Binding Term Sheet for Two Products with Panag Pharma
– Momentum Public Relations –
Press Release: March 14, 2017
Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), announced today it has entered into a binding term sheet with Panag Pharma Inc. for the development and commercialization of novel cannabinoid based formulations for the treatment of pain and inflammation. Combined total market potential of both products in the USA in 2014 is estimated over US$5.5 billion.
Per the binding term sheet, Tetra will have exclusive access to sell the ocular and topical drug products in North America with right of first negotiation for outside U.S. and Canadian territories. In addition, Tetra will have a right of first negotiation for future products.
Tetra will be working in close collaboration with Panag’s team of experts to ensure a rapid and successful development. Tetra shall be responsible for 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of the research and development of the Licensed Products. Tetra will own and control all regulatory approvals in the Territory, including the application and any other marketing authorizations within the Territory and shall be responsible for all aspects of commercializing the drug products.
Panag has developed potential new cannabinoid-based therapies for ocular and topical anti-inflammatory and pain markets. The total ocular anti-inflammatory market was estimated at over $3 billion in the USA in 2014 and includes conditions such as post-op inflammation, allergic conjunctivitis and inflammatory dry eye. Panag also developed a cannabinoid topical drug product for the treatment of local neuropathic and non-neuropathic pain. In 2014, the over the counter sales of topical analgesics were estimated at over $2.5 billion according to IMS.
“This announcement further demonstrates Tetra’s commitment to shareholders to add future products to our product portfolio in an effort of building a leading bio- pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “This will further allow Tetra to generate revenues in 2017 through its partnership with Panag. Tetra is going to work closely with Panag to exploit its innovative technology that indirectly acts on the CB2 receptor with the goal of launching several products in the retail market. This is in-line with Tetra’s goal of commercializing products pending legalization.”
According to Guy Chamberland, Chief Scientific Officer of Tetra Bio-Pharma, “We are going to prioritize the development of the ocular therapy as this is a promising innovative product and the potential financial reward will be significant. Tetra had already positioned itself to become a leader in topical pain relief with its PPTGR technology. With the Panag partnership, Tetra is going to modify its development plans to accelerate bringing an innovative cannabinoid topical drug product to the market. The Panag team is going to strengthen Tetra’s overall scientific knowledge and expertise base making it one of the leading biotechnology companies developing cannabinoid-based therapies.”
About Panag Pharma:
Panag Pharma Inc. is a Canadian based bio-tech company focused on the development of novel cannabinoid based formulations for the treatment of pain and inflammation. Panag believes that pain relief should be safe, non-addictive and above all; effective. The Panag Pharma team of PhD scientists and medical doctors are among the world’s leading researchers and clinicians in the area of pain treatment and management. They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag’s current pipeline of pain relief products include formulations for the topical application to the skin, the eye and other mucous membranes. Recently approved by Health Canada and currently undergoing clinical trials, Panag Pharma’s Topical AOTC provides a new approach to the treatment of chronic pain and inflammation.
About Tetra Bio-Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
- Published in Bio technology, Medical Marijuana, News Home, Tetra Bio Pharma
Cruz Cobalt agreement for Chicken Hawk
Cruz Cobalt agreement for Chicken Hawk
– Momentum Public Relations –
Press Release: March 13, 2017
2017-03-13 16:11 ET – Property Agreement
The TSX Venture Exchange has accepted for filing an agreement dated Feb. 27, 2017, between Cruz Cobalt Corp. and Chancellor Corp. (Dane Brown), whereby Cruz Cobalt is acquiring a 100-per-cent interest in the Chicken Hawk prospect in southwestern Montana. In consideration, the company will issue three million common shares.
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Cruz Cobalt, Mining, News Home
Anfield appoints Lumadue VP, U sales and marketing
Anfield appoints Lumadue VP, U sales and marketing
Momentum Public Relations
Press Release: March 13, 2017
Mr. Corey Dias reports
ANFIELD RESOURCES INC. ANNOUNCES VICE PRESIDENT, URANIUM SALES AND MARKETING
Robert Scott Lumadue has joined Anfield Resources Inc. as vice-president, uranium sales and marketing. Mr. Lumadue’s 38 years of relevant work experience includes four years with uranium producer Uranium One Americas as part of its uranium sales team, 12 years with U.S. utility Duke Energy Corp., 17 years with uranium conversion company ConverDyn and five years with Nuexco Trading Corp.
Corey Dias, Anfield’s chief executive officer, stated: “We are very pleased with the addition of Scott Lumadue as Anfield’s vice-president of uranium sales and marketing. Mr. Lumadue’s extensive experience within the nuclear sector will be a tremendous asset to the company. His long-term relationships with U.S. utilities and nuclear conversion facilities provide Anfield with a unique opportunity to leverage its improving uranium production position through the pursuit of long-term utility sales contracts. Anfield continues to strengthen its market position not only through strategic property and process acquisitions, but also through the addition of key personnel. By executing on this strategy, Anfield’s value proposition continues to gain greater appeal.”
About Anfield Resources Inc.
Anfield is an energy metals development and near-term production company that is committed to becoming a top-tier energy-related fuels supplier by creating value through sustainable, efficient growth in its energy metals assets.
We seek Safe Harbor.
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Anfield Resources, Mining, News Home
Making Canada’s capital a ‘smart city’
Making Canada’s capital a ‘smart city’
How can municipalities use the technology at residents’ fingertips to make life easier?
A number of civic, academic and business leaders will gather today to envision how Ottawa and Gatineau can become “smart cities” of the future.
Transit riders can already track when buses will arrive and drivers can add money to parking meters via their phones.
Driverless cars could be tested on the streets of Kanata this summer.
But things are moving quickly.
Data analytics, cybersecurity and the internet of things are transforming business, and cities are grappling with how to use those interconnections to help their residents, according to John Smit, acting director of economic development for the City of Ottawa.
Smit will be speaking at the conference put on by Library and Archives Canada and the University of Ottawa. The mayor of Gatineau and CEO of the National Capital Commission, as well as researchers and business executives, will all weigh in on what the future could look like.
“Ten years ago what you were able to do with your flip phone and what you’re able to do with your phone today are like night and day, and could you have predicted that 10 years ago?” Smit said.
Sensors and ‘smart’ devices
In the same way microwaves were a new convenience a generation ago, connected technologies should make life easier for people, said Campbell Patterson, a Kingston-based consultant who will also speak at Monday’s event.
Patterson sees a future where technology allows people to receive health care, education, and do work without leaving home, which will mean less wear and tear on roads and fewer greenhouse gas emissions.
Smart technologies are already allowing cities to gather data to manage everything from garbage, to water, to traffic, and help them save money and time, he said.
For instance, in Barcelona, Spain, the municipality has sensors in garbage bins so that trucks only empty them when needed, he said.
“The prediction is there will be 50 billion sensors deployed [worldwide] by 2020,” said Patterson.
For instance, autonomous vehicles could lead cities to install sensors on roads, Smit suggested.
Broadband is this century’s railway: consultant
But in such an interconnected world, Patterson said a city that doesn’t invest in broadband service stands to leave its residents and businesses behind.
“A municipality needs to be thinking about equitable access to the internet, and broadband infrastructure to support that, in the same way they think about investments in roads, water and electricity systems, that these are fundamental to the well-being of the community,” he said.
And municipalities shouldn’t leave it up to private telecommunications companies to beef up networks when they see fit, Patterson said.
“As long as downtown Toronto has better connectivity than everyone else, then the people who live there have a competitive advantage over everyone else,” he said
At the City of Ottawa, Smit knows consistent broadband access for everyone is one piece of the puzzle.
Staff are figuring out where to focus the municipality’s efforts to make Ottawa a “smart city,” and how to tie that in with the steps being taken by Hydro Ottawa and the economic development agency Invest Ottawa.
That overarching strategy is expected to be presented to councillors this spring or summer, Smit said.
By Kate Porter, CBC News
- Published in Blog, Imex Systems, Mobile Technology, News Home, Technology
Prince of Pot Being Popped at Pearson En Route to Pot Festival Appears to Prompt Pot Stocks
Smoke and Mirrors in the Market:
Prince of Pot Being Popped at Pearson En Route to Pot Festival Appears to Prompt Pot Stocks
Marijuana stock prices went on something of a roller coaster ride last week. In Canada it looks as if a combination of factors drove down valuations. To begin with, two class action law suits were filed against licensed medical marijuana producers, Mettrum Ltd., and OrganiGram Inc. which may have driven down the market. The two companies shipped product that contained toxic pesticide residues.
Pot stock prices revived when Marc Emery’s Cannabis Culture “dispensaries” in Ottawa, Toronto, Hamilton and Vancouver were raided and The Prince or Pot himself, Marc Emery and his wife Jodie, presumably the Princess of Pot were arrested at Pearson International Airport as they were on their way to a marijuana festival in Spain.
The smart money has argued that pot stocks fell back because they had been oversold. Investors have been figuring in the profits that will flow when legalization takes place and the doors to a much wider market opened. Bill Blair, the former police chief who is Ottawa’s point man on legalization recently said that a marijuana legalization bill will be tabled this spring. He has also said that Ottawa will take its time to make sure they get it right. It now looks as if the elephant next door may have had more to do in driving Canadian marijuana stocks down than Mettrum and OrganiGram.
Trump’s new attorney general Jeff Sessions, well known for calling a white lawyer a race traitor for taking on a voting rights case, and as an anti-marijuana advocate, pronounced not once but twice last week, that he would enforce American federal marijuana laws in an appropriate way. This may open a rift between the states and the American federal governments because 29 states have legalized medical marijuana and 8 states have legalized recreational marijuana. Sessions has also been described as Donald J. Trump’s intellectual godfather.
Canadian marijuana stocks may have rebounded because Canadian producers have taken action to deal with the contamination issue. Mettrum and OrganiGram have both issued voluntary recalls. Their executive suites have also been reshuffled. The Cannabis Canada Association which includes almost every licensed medical marijuana producer has also voted for mandatory product testing.
At this point you may be asking yourself how is this going to affect companies like Tetra Bio Pharma (TBP:CSE) which is concentrating on scientifically developing and producing marijuana derived drugs for the treatment of chronic pain and other ailments. The simple answer is that this is a minor tempest in a minor teacup that won’t affect serious pharmaceutical companies. Companies like Tetra which are run by experienced research scientists with a history that includes bringing botanically derived drugs to market know that you can’t fudge the science. Tetra knows this well enough to be engaged in developing its own strain of marijuana to make sure that precise and scientifically measured doses will be delivered.
As for the marijuana companies listed on the TSX chances are that they will rebound as marijuana enthusiasts keep pushing the stock prices up. Remember, they have been waiting for this moment for 30 or 40 years.
As for the Emerys, they seem to be convinced that pot has already been legalized and simply not paid any attention to the numerous times the prime minister has said that until the marijuana laws are changed they remain in effect. We all know the market can be unpredictable but even so, it’s hard to believe the arrest of a well known gadfly, his wife and employees would drive up the price of what to all extents and purposes is an agricultural commodity. After all, people who break the law are arrested many times a day.
No, the recent Canadian arrests are more about market share and who gets to sell it rather than anything else. What the federal government has done is signal that it is not going to tolerate a wild west marijuana trade after legalization. In all probability the liberals will put in place a highly regulated sales environment to prevent criminal gangs from profiting.
Meanwhile, south of the border, American lawyers are advising their marijuana producing clients to remember to dot their i’s and cross their t’s. Just as Al Capone was finally sent to jail for income tax evasion they are suggesting that Sessions will launch his anti-marijuana jihad by prosecuting them for failing to meet labour standards, accounting standards or paying all their federal taxes. Sessions also has a history of playing fast and loose with the law. As a prosecutor in Arkansas he had a history of filing indictments against Democrats who had a chance to win against Republican candidates in local elections.
- Published in Blog, Medical Marijuana, Tetra Bio Pharma
Cobalt’s surge attracts string of market hopefuls
Cobalt’s surge attracts string of market hopefuls
Like moths drawn irresistibly to light, the surge in the price of cobalt over the past few months has sponsored a couple of quick sharemarket floats and a rush of explorers hoping to latch onto the latest signs of life among some of the more exotic metals.
Just as lithium has won a lot of speculative investor support on the back of the prospects of rising demand with increased battery usage thanks to electric cars, even though any demand from this source is a decade away, at the very least, now it is cobalt’s turn.
Also giving cobalt a lift was the criticism of Apple Computer for sourcing its supplies of the material from uncontrolled mines in Congo, along with security issues in parts of that country that have raised additional questions over the security of supply.
Apple has said it will tighten control over its purchases of cobalt to avoid both child labour and harsh working conditions, although it has also said it wants to avoid causing too much disruption to the miners who need the income from supplying the high-tech giant.
In the process, the price of cobalt has surged around 40 per cent over the past few months to more than $50,000 a tonne, with the speed of the rally catching may in the market by surprise.
So, for a material that has been mostly an unwanted byproduct of nickel or copper mines, with usually very little value, the surge in its price has raised the prospect that standalone cobalt mines could be developed if the price rise proves to be sustained.
Geoff Hill, long-time investment banker and corporate adviser, initially to John Spalvins who spun a tug boat operator in Adelaide to a sprawling conglomerate owning breweries and department stores last century, was quick out of the blocks, launching a $10 million raising for Cobalt Blue. It was issuing shares at 20¢ in February that are now trading at more than 30¢.
Ditto for Ardea Resources, which also issued shares last month at 20¢ which are trading at more than 50¢ a piece after a recent run to more than 90¢. It was spun out of Heron Resources, and it is already touting a pre-feasibility study on some cobalt-nickel acreage near Kalgoorlie, which it is calling the “largest resource in the developed world”.
A host of others have figured out that pegging cobalt acreage might just give their share price sufficient lift to justify a quick fund-raising so they can eke out another few months of life. Last Tuesday, it was Latin American Resources disclosing acreage in Argentina and later in the week Cohiba Minerals was updating the market on some acreage it is looking at.
“There are a lot of companies looking at the potential, with what they’ve got,” said Mike Millikan, analyst with Hartley, pointing to Independence Group with its Nova project. “At the moment there is a lot of interest but it is anyone’s guess how long it will last.”
Brian Robins
- Published in Blog, Cruz Cobalt, Mining
HealthSpace (HS:CSE) Announces Contract with KFL&A Public Health and Issues Stock Options
HealthSpace (HS:CSE) Announces Contract with KFL&A Public Health and Issues Stock Options
– Momentum Public Relations –
Press Release: March 9, 2017
HealthSpace Data Systems Ltd . (the “Company” or “HealthSpace”) is pleased to announce that the Company has signed a three-year contract, with renewal options, to provide its environmental inspection software and services to KFL&A Public Health in Ontario. KFLA is a local public health agency with over 200 staff and 150 volunteers that delivers public health programs and services to the more than 180,000 residents of the Kingston, Frontenac and Lennox & Addington area .
HealthSpace President, Joseph Willmott stated “we are delighted to have KFL&A Public Health as a client as they are considered one of the more progressive health units in Ontario.” The contract is worth $56,420.
The Company also announces that it has g ranted an aggregate of 75,000 stock options to a consultant of the company. Each stock option entitles the holder to purchase one common share of the company at a price of .08 cents per common share for a period of five years from the grant date.
About HealthSpace Data Systems Ltd.
HealthSpace is an industry leading technology company currently providing inspection, information, communication and data management systems for federal, state, county and municipal governments. Over the last decade, HealthSpace has successfully developed both enterprise and mobile internet-based applications currently serving over 300 state and local government organizations across North America. HealthSpace currently offers the only integrated inspection, administration and analytics product suite across all platforms in North America. Further HealthSpace now delivers it’s government grade technologies to private businesses enabling them to gain visibility and predictability into their own organizations and move from a reactive to a proactive operational status. HealthSpace continues to deliver focused service and innovative solutions to government organizations, while expanding into commercial enterprise verticals to enable new customers with proactive environmental health best practices and policies.
- Published in Health Space, Life Sciences, News Home
Tetra Bio-Pharma Announces that the Delay in Legalization of Marijuana Does Not Affect its Drug Development & Commercialization Plans
Tetra Bio-Pharma (TBP:CSE) Announces that the Delay in Legalization of Marijuana Does Not Affect its Drug Development & Commercialization Plans
– Momentum Public Relations –
Press Release: March 9, 2017
Tetra Bio-Pharma Inc. (“Tetra”, “TBP” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a biotechnology company specialized in the development and commercialization of Cannabis-based prescription drugs announced that the delay in legalization of marijuana does not affect its commercialization plans for 2017. AgroTek Health (AGT) for the over-the-counter self-care consumer markets is on schedule for the launch of its first Cannabis-derived (THC- and CBD-free) product in 2017.
Based on Tetra’s experience in government affairs, the Company had anticipated delays in the legalization due to the complexity associated with this endeavour. Subsequent to this assessment, Tetra had initiated a plan to commercialize THC- and CBD-free Cannabis derived products. In addition, Tetra entered into a partnership with McGill University and Ford’s Family Pharmacy and Wellness Centre to ensure timely commercialization of these products. Tetra is also discussing with several Licensed Producers to ensure a supply of Cannabis and or to enter into a partnership with AGT.
“Tetra is making tremendous progress in the execution of its strategy to become a leading biopharmaceutical company in developing and commercializing cannabis prescription drugs,” said Mr. Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “I am proud to report to shareholders that AGT is on schedule to bring cannabis-derived products to the OTC market after it strategically developed its commercialization plans to partner with Drs. Peter Ford and Stan Kubow after anticipating delays in the legalization of marijuana. We look forward to keeping shareholders updated on our future plans of strengthening Tetra into a bio-pharmaceutical organization.”
All TBP partners and any future partners or suppliers of Cannabis will be subject to regular quality audits to ensure compliance with Canadian regulations and that the Cannabis raw material conforms to quality standards for an oral pharmaceutical product. The quality audit includes third party independent testing for impurities such as pesticides. All of these Licensed Producers will be subject to potential inspections by Health Canada’s Inspectorate or the USA Food and Drug Administration. TBP and its partners recognize that this is part of the responsibility of bringing quality safe products to consumers.
In autumn 2016, TBP announced that it had entered into a partnership with Dr. Stan Kubow, School of Nutrition and Dietetics, McGill University after obtaining an NSERC ENGAGE grant for the development of proprietary Cannabis-extracts for the development and commercialization of nutritional and heath care supplements as well as topical natural products and cosmetics. In February 2017, Controlled Drug Substances, Health Canada, issued the exemption required for the development of these proprietary extracts. This innovative project is expected to deliver at least one commercial nutritional supplement later this year. AGT is also working with Ford’s Family Pharmacy and Wellness Centre to commercialize one or more topical THC- and CBD-free products.
About Tetra Bio-Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
- Published in Bio technology, Medical Marijuana, News Home, Tetra Bio Pharma